A Comparison Of The Effect Of Target-Controlled Infusion Anesthesia And Inhalation Anesthesia

November 15, 2024 updated by: Sibel Seçkin Pehlivan, TC Erciyes University

A Comparison Of The Effect Of Target-Controlled Infusion Anesthesia And Inhalation Anesthesia On Patient Outcomes In Pediatric Patients Undergoing Endovascular Intervention

A total of 70 patients who underwent angiographic examination, ASD closure, VSD closure, PDA closure and aortic balloon dilatation were included in this study.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

A total of 70 patients who underwent angiographic examination, ASD closure, VSD closure, PDA closure and aortic balloon dilatation were included in this study. Patients underwent standard electrocardiography (ECG) monitoring with heart rate (HR), noninvasive blood pressure (NIKB), peripheral oxygen saturation (SpO2) and Bispectral index (BIS). Baseline NIKB, SpO2 and HR were recorded before the procedure, intraoperatively and in the postoperative recovery unit. In the postoperative recovery unit, the patient's recovery time was also evaluated and recorded with the Modified Aldrete Recovery Score.

Study Type

Observational

Enrollment (Actual)

70

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Talas
      • Kayseri, Talas, Turkey, 38039
        • Sibel Seckin Pehlivan

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Probability Sample

Study Population

children ages 3 to 18 with heart disease

Description

Inclusion Criteria:

  1. Children weighing over 10 kg and between the ages of 3-18 who will undergo angiography
  2. Patients who are not allergic to the drugs used

Exclusion Criteria:

  1. ASA Ⅳ patients
  2. Patients with Diabetes Mellitus
  3. Patients with severe lung disease
  4. Patients with psychiatric disorders
  5. Patients with opioid addiction -

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
group 1
Total intravenous anesthesia with target-controlled infusion (TCI/TIVA) was applied as an anesthesia method to be applied to patients during cardiology angiography procedures.
: The aim of this study was to evaluate the effects of total intravenous anesthesia with target-controlled infusion (TCI/TIVA) on intraoperative hemodynamic parameters and postoperative awakening criteria in pediatric endovascular intervention patients
Other Names:
  • Inhalatıon
Group 2
In the anesthesia method to be applied to patients during cardiology angiography procedures, inhalation anesthesia was applied.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
intraoperative period
Time Frame: an average of 2 hours
During cardiology angiography procedures, patients' heart rate,measurements will be evaluated.
an average of 2 hours
postoperative period
Time Frame: an average of 2 hours
During cardiology angiography procedures, patients' eye opening time will be evaluated.
an average of 2 hours
hemodynamic parameters
Time Frame: an average of 2 hours
During cardiology angiography procedures, patienheart ts' mean arterial pressure (MAP),measurements will be evaluated.
an average of 2 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Modified Aldrete Recovery Score
Time Frame: during the processing period
Modified Aldrete Recovery Score will be evaluated in the postoperative period
during the processing period

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Sibel Pehlivan, MD, TC Erciyes University
  • Principal Investigator: Mustafa Cakıllı, Department of Anaesthesiology and Reanimation, Yozgat City Hospital,
  • Principal Investigator: Ozlem OZ GERGIN, MD, Department of Anaesthesiology and Reanimation, Medical Faculty, Erciyes University
  • Principal Investigator: Ali BAYKAN, Prof, Department of Pedıatrıc Cardiology, Medical Faculty, Erciyes University
  • Principal Investigator: Recep AKSU, Prof, Department of Anaesthesiology and Reanimation, Medical Faculty, Erciyes University
  • Principal Investigator: Karamehmet YILDIZ, prof, Department of Anaesthesiology and Reanimation, Medical Faculty, Erciyes University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2022

Primary Completion (Actual)

September 1, 2023

Study Completion (Actual)

October 1, 2023

Study Registration Dates

First Submitted

January 12, 2024

First Submitted That Met QC Criteria

February 16, 2024

First Posted (Actual)

February 20, 2024

Study Record Updates

Last Update Posted (Estimated)

November 19, 2024

Last Update Submitted That Met QC Criteria

November 15, 2024

Last Verified

November 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Data can be shared upon reasonable request to the corresponding author.

IPD Sharing Time Frame

Data can be shared upon reasonable request to the corresponding author.

IPD Sharing Access Criteria

Data can be shared upon reasonable request to the corresponding author.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • ANALYTIC_CODE
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe